Yasushi Mochizuki
Overview
Explore the profile of Yasushi Mochizuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuda T, Yamada S, Tsuchiyama A, Kurata H, Mukae Y, Okano S, et al.
IJU Case Rep
. 2025 Mar;
8(2):142-145.
PMID: 40034899
Introduction: Desmoid tumors are rare, locally invasive, non-metastasizing intermediate grade neoplasms. According to the organ procurement and transplantation network report, approximately one million solid organ transplants have been performed globally,...
2.
Iwata M, Uramatsu T, Sakamoto R, Torigoe K, Yamashita A, Abe S, et al.
CEN Case Rep
. 2025 Feb;
PMID: 39948236
A 60-year-old woman with diabetic nephropathy was diagnosed with end-stage kidney disease and underwent peritoneal dialysis (PD) (X-3 years). Due to decreased residual renal function, she commenced combined PD and...
3.
Honda H, Matsuo T, Mori S, Araki K, Mitsunari K, Ohba K, et al.
Hinyokika Kiyo
. 2024 Dec;
70(11):361-366.
PMID: 39710840
In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous...
4.
Matsuo T, Kakita S, Honda H, Mori S, Araki K, Mitsunari K, et al.
Medicina (Kaunas)
. 2024 Nov;
60(11).
PMID: 39597014
: This study aimed to investigate the relationship between lower urinary tract symptoms (LUTS) and tooth loss due to chronic periodontitis. : A total of 232 patients aged 40 years...
5.
Tsuyuki T, Abe S, Otsuka E, Tsuji K, Torigoe K, Yamashita A, et al.
CEN Case Rep
. 2024 Nov;
PMID: 39560709
Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD, and its prevention and treatment are important for reducing patient morbidity and mortality. Reports of PD-associated peritonitis caused by Corynebacterium...
6.
Fukushima H, Mitsunari K, Harada J, Nakamura Y, Matsuo T, Ohba K, et al.
In Vivo
. 2024 Oct;
38(6):2729-2734.
PMID: 39477409
Background/aim: Hypertension does not always improve after adrenalectomy for primary aldosteronism (PA), and antihypertensive medications cannot always be discontinued. This study aimed to identify the prognostic predictors of hypertension following...
7.
Mori S, Matsuo T, Honda H, Araki K, Mitsunari K, Ohba K, et al.
IJU Case Rep
. 2024 Jul;
7(4):324-328.
PMID: 38966765
Introduction: Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis. Case Presentation: Case 1: An 85-year-old man underwent hemodialysis...
8.
Mitsunari K, Fukushima H, Kurata H, Harada J, Nakamura Y, Matsuo T, et al.
Anticancer Res
. 2024 Jun;
44(7):3149-3154.
PMID: 38925837
Background/aim: The primary objective of this study was to identify predictors for biochemical recurrence (BCR) within 2 years following robot-assisted radical prostatectomy (RARP). Identifying predictors will enable insights that enhance...
9.
Ohba K, Nakanishi H, Kawada K, Nakamura Y, Mitsunari K, Matsuo T, et al.
Jpn J Clin Oncol
. 2024 Apr;
54(7):827-832.
PMID: 38651176
Objective: Nivolumab plus ipilimumab is a recommended first-line therapy regimen for metastatic renal cell carcinoma. However, it is not clear which patient characteristics are associated with its effectiveness. Methods: We...
10.
Mukae Y, Ohba K, Araki K, Nakamura Y, Nakanishi H, Yasuda T, et al.
Int Cancer Conf J
. 2024 Mar;
13(2):129-133.
PMID: 38524652
Primary bladder adenocarcinomas comprise 0.5-2% of all epithelial bladder neoplasms. Of these, primary signet-ring cell carcinoma of the bladder is particularly rare, accounting for 0.24% of all bladder malignancies. This...